Editorial

European and American hypertension guidelines and goal blood pressure: Relevance to India

1. Introduction

Hypertension remains as a major risk factor for premature mortality and excessive morbidity throughout the world. Chronic hypertension is a predisposing factor in the development of coronary artery disease (CAD), cerebrovascular disease (CeVD), systemic atherosclerosis, congestive heart failure (CHF), chronic kidney disease (CKD), and dementia. Together, these sequelae of hypertension exert a critical impact on public health, medical expenses and the health system(s). Despite various regional and global efforts to control hypertension, its prevalence world-wide remains high with an estimated figure or more than 1.13 billion.1

The Global Burden of Disease (GBD) study has once again reiterated that hypertension is perhaps the most important risk factor for morbidity and mortality.2 Data emanating from India are consistent with this observation and demonstrate an emerging and growing risk from hypertension in this country.3 A number of studies have shown that the chronic disease burden from hypertension is escalating in India with no end in sight.4–6 The unfavorable winds of cardiovascular disease (CVD) in India affect not only the urban population but also the rural settings as well.7 Despite some regional variations, it can be concluded that the average prevalence of hypertension [blood pressure (BP) >140/90 mmHg] in India is 25%, which translates into more than 250 million adults! Thus, the problem of hypertension in India is tragic and overwhelming, irrespective of changing definitions.

The latest hypertension guideline from the American College of Cardiology (ACC)/American Heart Association (AHA) and other partnering societies has radically revised the thresholds to diagnose and treat hypertension8 (Table 1). The cut off for the diagnosis of hypertension has been lowered to >130/80 mmHg and the threshold target blood pressure goal has been changed to <130/80 mmHg. According to this new definition of hypertension, many more millions of adults suddenly require surveillance and perhaps treatment. The new American definition of hypertension has triggered some criticism and a host of viewpoints9–12 and the debate will surely continue for some more time.

The European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) have released their new guideline for hypertension on June 9, 2018.13–15 This latest ESC/ESH guideline is a successor to the previous guideline issued in 2013. During this intervening period of 5 years, the task force collected and analyzed the data related to the risks imposed by hypertension and the pandemic of CVD and proposed certain preventive and therapeutic strategies. In formulating the new guideline, the Committee conducted extensive assessment and appraisal of numerous studies, especially the controlled trials, meta-analysis, and a thorough review of the published literature. The final guideline was issued following the standard basis of class of recommendation and level of evidence.

The European guideline has not changed the classification and definition of hypertension, i.e., BP > 140/90 mmHg (Tables 2 and 3). This is in sharp contrast to American definition of hypertension, i.e., BP > 130/80 mmHg. The American and European differences in the thresholds to label hypertension are significant and of considerable public health importance. How is it possible that the new sets of guidelines released so close to each other differed on the definition of hypertension? This has baffled many, understandably so, and has led to significant confusion. The truth is that the American guideline relied heavily on the clinical studies showing incremental benefits of cardiovascular protection with decreasing BP levels whereas the European guideline relied heavily on the population attributable risk from epidemiological observations. Thus, it is the difference in the objectives of diagnosing and managing hypertension that underlie the differences in the definition of hypertension in the two guidelines. This, in essence, is the divergence between the trans-Atlantic guidelines. However, it is very important to note that both guidelines converge on common BP treatment targets of <130/80 mmHg13–15 (Tables 4 and 5).

The European guideline recommends that the objective of treatment should be to lower the BP to <140/90 mmHg and the “treated” value should be <130/80 mmHg or lower and a diastolic BP target should be <80 mmHg for all patients (Fig. 1). Interestingly, the European guideline recommends that in patients <65 years receiving anti-hypertensive drugs, systolic BP be lowered to 120–130 mmHg in most patients. That’s the catch! In other words, it is implicated in the European guideline that treated BP in adults should even be lower than what was proposed in the American guideline! Very interesting and intriguing indeed! Regardless of the differences in the definition of hypertension, both the guidelines agree on the point that more aggressive control of hypertension is needed than what has been recommended so far and that a treated BP level of 140/90 mmHg is no longer acceptable in most patients.

What is the relevance of the new guidelines to control hypertension in the Indian context? And what should be the take home message for the Indian practitioners? Due to the unrelenting...
Table 1
Blood pressure categories in the 2017 American College of Cardiology/American Heart Association in context to the existing definitions.

| Systolic, diastolic blood pressure (mm Hg) | JNC 710 | 2017 ACC/AHA8 | Indian Hypertension Guideline30 |
|-------------------------------------------|---------|---------------|-------------------------------|
| < 120 and < 80                            | Normal blood pressure | Normal blood pressure | Optimal |
| 120–129 and <80                           | Prehypertension | Elevated blood pressure | Normal |
| 130–139 or 80–89                          | Prehypertension | Stage 1 hypertension | High Normal |
| 140–159 or 90–99                          | Stage 1 hypertension | Stage 2 hypertension | Stage 1 hypertension |
| >160 or >100                              | Stage 2 hypertension | Stage 2 hypertension | Stage 2 hypertension |

ACC—American College of Cardiology; AHA—American Heart Association; JNC—Joint National Commission.

Table 2
The latest European classification of office blood pressure and definitions of hypertension grades.

| Category                        | Systolic blood pressure (mmHg) | Diastolic blood pressure (mmHg) |
|---------------------------------|---------------------------------|---------------------------------|
| Optimal                         | <120                            | and                             |
| Normal                          | 120–129                         | and/or                          |
| High normal                     | 130–139                         | and/or                          |
| Grade 1 hypertension            | 140–159                         | and/or                          |
| Grade 2 hypertension            | 160–179                         | and/or                          |
| Grade 3 hypertension            | ≥180                            | and                             |
| Isolated systolic hypertension  | ≥140                            | and                             |

Source—Williams B, Mancia G, et al. J Hypertens 2018 and Eur Heart J 2018, in press.

Table 3
European definitions of hypertension according to office, ambulatory, and home blood pressure levels.

| Category                        | Systolic (mmHg) | Diastolic (mmHg) |
|---------------------------------|-----------------|-----------------|
| **Office blood pressure**       | ≥140            |                 |
| **Ambulatory blood pressure**   |                 |                 |
| Daytime (or awake) mean         | ≥135            | ≥85             |
| Night-time (or asleep) mean     | ≥120            | ≥70             |
| 24-h mean                       | ≥130            | ≥80             |
| **Home blood pressure mean**    | ≥135            | ≥85             |

Source—Williams B, Mancia G, et al. J Hypertens 2018 and Eur Heart J 2018, in press.

Table 4
Key messages from the 2018 European hypertension guideline.

- The first objective is to lower the blood pressure to <140/90 mm Hg in all patients.
- A companion objective is to attain a target blood pressure of <130/80 mm Hg in most patients.
- A diastolic blood pressure target of <80 mm Hg should be considered for “all” patients with hypertension.
- In patients >65 years, the achieved systolic blood pressure level should be 120–130 mm Hg.
- In patients >65 years, the systolic blood pressure target should be 130 to 140 mm Hg.
- In diabetic patients on anti-hypertensive drugs, the systolic blood pressure should be 120–130 mm Hg.
- South Asians are at the highest risk from hypertension related disease burden.

Source—Williams B, Mancia G, et al. J Hypertens 2018 and Eur Heart J 2018, in press.

Table 5
Office blood pressure treatment targets recommended by the 2018 European hypertension guideline.

| Office systolic blood pressure treatment target ranges (mmHg) | Diastolic treatment target range (mmHg) |
|-------------------------------------------------------------|----------------------------------------|
| Hypertension + Diabetes + CKD + CAD + Stroke/TIA            |                                         |
| 18–65 years Target to 130 or lower if tolerated              | Target to 130 or lower if tolerated     |
| 65–79 years Target to <140 to 130 if tolerated              | Target to <140 to 130 if tolerated      |
| 80 years Target to <140 to 130 if tolerated                 | Target to <140 to 130 if tolerated      |
| Diastolic treatment target range <80 to 70                  |                                         |

CAD—coronary artery disease; CKD—chronic kidney disease; TIA—transient ischemic attack.
Source—Williams B, Mancia G, et al. J Hypertens 2018 and Eur Heart J 2018, in press.
Hypertension definitions

Blood pressure treatment goal is the same

Fig. 1. The latest American and European hypertension guidelines- divergent, yet convergent.

disease burden exerted by uncontrolled hypertension in India, the new guidelines are of impactful significance. India is under the grip of public health and medical expense crisis due to uncontrolled hypertension (by any definition). Even by applying the relatively loose and liberal definition of hypertension by the Indian hypertension guideline, the percentage of population with unabated and tenacious hypertension is too large with inevitable health consequences to the country. It is wise for India to adopt and embrace the best features of both the American and European guidelines. After all, the constitution of India was derived from absorbing the best features of European and American constitutions. We should apply the same theme to control hypertension more effectively in the Indian subcontinent already facing the brunt of cardiovascular tsunami. After all, hypertension is nothing but a hemodynamic malignancy. Let us catch it early and take appropriate preventing and “less conservative” therapeutic steps to prevent BP-mediated target organ damage. Time is now, not tomorrow, to win the battle against chronic disease burden by early diagnosis and less conservative treatment of hypertension. We cannot afford the loss of lives, illness, and diminution of national productivity triggered by elevated BP. It is imperative that a BP level of >130/80 mmHg (measured accurately) is a warning signal of impending disaster if the BP trends are not reversed. A substantial number of Indians experience disease progression at systolic BP level >130 mmHg and a diastolic BP level >80 mmHg17,18 (Figs. 2 and 3). Hence, to shield our large population from the cataclysmic ravages of high BP, the practitioners should aim for a goal BP of <130/80 mmHg in their patients with hypertension diagnosed by any definition. This therapeutic goal is non-negotiable as the European guideline has identified South Asians as the highest risk population at any level of BP. Patients with diabetes are at a high risk for premature and malignant CVD even at modest elevations in arterial BP. Since there is a high co-prevalence of diabetes and hypertension in India,18 the newer lower thresholds to diagnose and treat hypertension are especially relevant to India. Precious time should not be wasted in debating whether the new guidelines should be embraced by India. Enough is enough, hypertension begets hypertension. We need to accept the available evidence to extinguish the pernicious consequences of elevated BP by early diagnosis and by a war like footing to lower

Fig. 2. Risk of deaths and cerebrovascular accidents in relation to systolic blood pressure levels- data derived from the Mumbai/India Cohort Study. CVA- cerebrovascular accident; HR- hazard ratio; SBP- systolic blood pressure. (Adapted from reference17).

Fig. 3. Risk of deaths from ischemic heart disease in relation to systolic blood pressure levels- data derived from the Mumbai/India Cohort Study. HR- hazard ratio; IHD- ischemic heart disease; cerebrovascular accident; SBP- systolic blood pressure (Adapted from reference17).
the BP levels to the new thresholds with available and additional resources.

References

1. NCD Risk Factor Collaboration (NCD-RISC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55.

2. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1345–1422.

3. Anchala R, Kannuri NK, Pant H, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014;32:1170–1177.

4. Gupta R, Pandey RM, Misra A, et al. High prevalence and low hypertension awareness, treatment and control in Asian Indian women. J Hum Hypertens. 2012;26:585–593.

5. Gupta R, Deedwania PC, Achari V, et al. Normotension, prehypertension and hypertension in Asian Indians: prevalence, determinants, awareness, treatment and control. Am J Hypertens. 2013;26:83–94.

6. Bhanusali A, Dhandhania VK, Mohan D, et al. Prevalence of and risk factors for hypertension in urban and rural India: the ICMR INDIAB study. J Hum Hypertens. 2015;29:204–209.

7. Singh M, Kotwal A, Mittal C, Babu SR, Bharti S, Ram CVS. Prevalence and correlates of hypertension in a semi-rural population of South India. J Hum Hypertens. 2018;32:66–74.

8. Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/ASCVD Task Force on High Blood Pressure in Adults. ACC/AHA 2018 Guideline for the Prevention of High Blood Pressure in Adults. JAMA. 2018;320:1896–1918.

9. Wanner G, Ram CVS. Global impact of 2017 American Heart Association/American College of Cardiology, hypertension guidelines. J Am Soc Hypertens. 2018;12:67–68.

10. Ram CVS. Latest guidelines for hypertension: adopt and adapt. J Am Soc Hypertens. 2018;12:67–68.

11. Mancia G, Carrao G. A perspective from Italy. Circulation. 2018;137:889–890.

12. Mancia G, Carrao G. A perspective from Japan. Circulation. 2018;137:543–545.

13. Williams B, Mancia G. Barcelona, June 9, 2018 and others. ESC/ESH Guidelines for the Management of Arterial Hypertension Presented at the 28th European Meeting on Hypertension and Cardiovascular Protection. 2018.

14. Williams B, Mancia G, et al. ESC/ESH guidelines for the management of arterial hypertension. J Hypertens. 2018; in press.

15. Williams B, Mancia G, et al. ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; in press.

16. Indian guidelines on hypertension (JGH)-III. JAMI 2013;61(February 2) suppl.,

17. Pednekar MS, Gupta R, Gupta PC. Association of blood pressure and cardiovascular mortality in India: Mumbai cohort study. Am J Hypertens. 2009;22:1076–1084.

18. Geldsetzer P, Manne-Goehler J, Theilmann M, et al. Diabetes and hypertension in India: a nationally representative study of 1.3 million adults. JAMA Intern Med. 2018;178:363–372.

19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr. JL, Jones DW, Materson BJ, Oparil S, Wright Jr. JT Jr., Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.

C. Venkata S. Ram*  
Apollo Institute for Blood Pressure Management, World Hypertension League/South Asia Office, Apollo Hospitals, and Apollo Medical College, Hyderabad, India

Texas Blood Pressure Institute, DNA, UTSW Medical School, Dallas, USA

India Campus, Macquarie University, Medical School, Sydney, Australia

* Corresponding author.
E-mail address: drram_v@apollohospitals.com (C. Ram).

Available online 7 July 2018